Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antibody-drug conjugates
Biotech
Endometrial cancer data on Genmab’s Elahere rival beat forecast
The biotech reported a 50% unconfirmed response rate, beating the expectations of analysts to boost confidence ahead of a move into phase 3.
Nick Paul Taylor
May 23, 2025 9:22am
ADC Therapeutics calls time on sole clinical-stage candidate
May 14, 2025 9:55am
Mersana lays off 55% of staff, narrows focus to B7-H4 ADC
May 6, 2025 9:40am
Elevation faces activist investor demands to wind down
Apr 17, 2025 10:00am
BioNTech backing powers DualityBio toward $200M Hong Kong IPO
Apr 7, 2025 8:21am
Boehringer commits $31M to ADC R&D via NBE Therapeutics facility
Apr 3, 2025 5:30am
